Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment (Frontiers of Gastrointestinal Research Vol.28) （2010. 212 S. 23 fig., 31 tab.）

個数：

Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment (Frontiers of Gastrointestinal Research Vol.28) （2010. 212 S. 23 fig., 31 tab.）

Herausgegeben von Gerbes, A. L./ Rogler, G.

ウェブストア価格 ¥48,120（本体¥43,746）
KARGER（2010発売）
外貨定価 EUR 181.90
ポイント 437pt

在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
【重要ご説明事項】
1. 納期遅延や、ご入手不能となる場合がございます。
2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
3. 美品のご指定は承りかねます。

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Hardcover:ハードカバー版／ページ数 220 p.
言語 ENG
商品コード 9783805595919

Full Description

Ascites is the most frequent and hepatorenal syndrome the most lethal complication in liver cirrhosis. In recent years, major progress has been made regarding effective treatment of these complications, thus reducing mortality in patients. This publication highlights and critically appraises recent achievements and novel advances, and at the same time provides the background needed to grasp novel concepts. Topics treated include complications of paracentesis, the right choice of plasma expanders, and selection of patients who will experience survival benefit from transjugular intrahepatic portosystemic shunt. Hepatorenal syndrome, on the other hand, is responsible for a broad spectrum of manifestations caused by acute kidney injury, which until recently was considered a lethal condition. Drug treatments to improve renal function and prolong survival are therefore also discussed, including important issues for clinical outcome which are still under debate. Moreover, the role of combined kidney-liver transplantation versus conventional liver-only transplantation is addressed, as well as the use of vaptans in hyponatremia and their controversial role in the treatment of ascites. Renowned experts share their knowledge and expertise and provide an international perspective. Their contributions include up-to-date references and a bullet-point summary, making this publication most valuable for practitioners, clinicians and scientists in the field.

Preface: Gerbes, A.L.; Differential Diagnosis of Ascites: Appenrodt, B. Current Treatment Strategies: Diuretics: Bernardi, M.; Paracentesis: Sanyal, A.J.; Bajaj, J.S.; Shaw, J. Large-Volume Paracentesis: Which Plasma Expander? Terg, R.A.; Albumin: Not Just a Plasma Expander: Davies, N.A.; Garcia, R.; Proven, A.; Jalan, R.; Transjugular Intrahepatic Portosystemic Shunt for Ascites: Which Patients Will Benefit? Salerno, F.; Cazzaniga, M.; Spontaneous Bacterial Peritonitis - Prophylaxis and Treatment: Wiest, R.; Garcia-Tsao, G.; Clinical Implications of Hyponatremia in Cirrhosis: Heuman, D.M.; Vaptans for Ascites - Chances and Risks: Wong, F.; Cardiorenal Syndrome - A New Entity? Moller, S.; Krag, A.; Renal Failure in Cirrhosis: Gustot, T.; Moreau, R. Novel Definition of Hepatorenal Syndrome: Clinical Consequences: Fernandez, J.; Arroyo, V.; Role of Infections in Hepatorenal Syndrome: Wiest, R.; TIPS for HRS: Sauerbruch, T.; Appenrodt, B. Vasoconstrictor Therapy for Hepatorenal Syndrome: Yeo, C.-M.; Garcia-Tsao, G.; Terlipressin for Hepatorenal Syndrome: The US Experience: Musana, A.K.; Sanyal, A.J.; Terlipressin for Hepatorenal Syndrome: Predictors of Response: Cardenas, A.; Gines, P.; Safety of Terlipressin for Hepatorenal Syndrome: Krag, A.; Moller, S.; Terlipressin for Hepatorenal Syndrome: Novel Strategies and Future Perspectives: Angeli, P.; Hepatorenal Syndrome and Liver Transplantation: Gonwa, T.A.